Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionManufacturers Life Insurance Company, The
Latest Disclosed Ownership39,660 shares
Latest Disclosed Value $ 1,178,299
Manufacturers Life Insurance Company, The reports 0.09% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Manufacturers Life Insurance Company, The filed a 13F-HR form disclosing ownership of 39,660 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $1,178,299 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 39,696 shares of Travere Therapeutics, Inc.. This represents a change in shares of -0.09% during the quarter. The current value of the position is $1,792,632 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 39,660 -36 -0.09 1,178 -22.30 0.0010
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 39,696 -4,933 -11.05 1,517 42.21 0.0012
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 44,629 527 1.19 1,067 63.50 0.0009
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 44,102 2,613 6.30 653 -12.25 0.0006
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 41,489 14,151 51.76 743 56.09 0.0007
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 27,338 -19,707 -41.89 476 -27.66 0.0004
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 47,045 17,931 61.59 658 175.31 0.0006
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 29,114 264 0.92 239 7.66 0.0002
2024-05-14 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 28,850 -8,352 -22.45 222 -33.53 0.0002
2024-02-13 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 37,202 -241 -0.64 334 0.00 0.0002
2023-11-15 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 37,443 7,924 26.84 335 -26.27 0.0002
2023-08-11 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 29,519 4,890 19.85 453 -18.08 0.0003
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 24,629 169 0.69 554 7.59 0.0003
2023-08-11 2022-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 24,460 -519,329 -95.50 514 -96.16 0.0003
2023-02-13 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 24,460 -519,329 514 0.0003
2023-08-11 2022-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 543,789 -504 -0.09 13,399 1.59 0.0093
2022-11-03 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 543,789 -504 13,399 0.0094
2023-08-11 2022-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 544,293 247 0.05 13,188 -5.93 0.0092
2022-08-15 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 544,293 247 13,188 0.0092
2023-08-11 2022-03-31 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 544,046 -5,442 -0.99 14,020 -16.90 0.0092
2022-08-15 2022-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 544,046 -5,442 14,020 0.0088
2022-05-20 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 544,046 -5,442 14,020 0.0118
2022-02-16 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 549,488 -156,437 -22.16 16,871 -1.45 0.0103
2021-11-12 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 705,925 -3,577 -0.50 17,119 65.38 0.0140
2021-08-12 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 709,502 -1,600,385 -69.28 10,351 -82.05 0.0084
2021-05-03 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,309,887 123,057 5.63 57,678 -3.23 0.0500
2021-02-12 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,186,830 -24,311 -1.10 59,603 46.02 0.0550
2020-11-09 2020-09-30 13F RETROPHIN COM 761299106 2,211,141 29,791 1.37 40,818 -5.16 0.0421
2020-08-10 2020-06-30 13F RETROPHIN COM 761299106 2,181,350 -163,067 -6.96 43,038 25.82 0.0404
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 2,344,417 1,685 0.07 34,205 2.82 0.0379
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 2,342,732 -979 -0.04 33,267 19.48 0.0350
2019-11-12 2019-09-30 13F RETROPHIN COM 761299106 2,343,711 206,908 9.68 27,843 -35.14 0.0312
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 2,136,803 192,515 9.90 42,928 -2.43 0.0500
2019-05-13 2019-03-31 13F RETROPHIN COM 761299106 1,944,288 73,284 3.92 43,999 3.92 0.0476
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 1,871,004 25,601 1.39 42,341 -20.14 0.0534
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 1,845,403 327,194 21.55 53,018 28.11 0.0560
2018-08-14 2018-06-30 13F RETROPHIN COM 761299106 1,518,209 1,488,347 4,984.08 41,386 6,095.51 0.0452
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 29,862 222 0.75 668 6.71 0.0007
2018-02-08 2017-12-31 13F RETROPHIN COM 761299106 29,640 615 2.12 626 -13.42 0.0007
2017-11-14 2017-09-30 13F RETROPHIN COM 761299106 29,025 -1,052 -3.50 723 24.01 0.0009
2017-08-15 2017-06-30 13F RETROPHIN COM 761299106 30,077 1,733 6.11 583 11.26 0.0007
2017-05-15 2017-03-31 13F RETROPHIN COM 761299106 28,344 3,362 13.46 524 10.78 0.0007
2017-02-14 2016-12-31 13F RETROPHIN COM 761299106 24,982 -20 -0.08 473 -15.38 0.0007
2016-11-14 2016-09-30 13F RETROPHIN COM 761299106 25,002 49 0.20 559 25.62 0.0008
2016-08-15 2016-06-30 13F RETROPHIN COM 761299106 24,953 1,794 7.75 445 43.55 0.0007
2016-05-10 2016-03-31 13F RETROPHIN COM 761299106 23,159 192 0.84 310 -30.02 0.0003
2016-02-16 2015-12-31 13F RETROPHIN COM 761299106 22,967 245 1.08 443 -3.70 0.0004
2015-11-13 2015-09-30 13F RETROPHIN COM 761299106 22,722 560 2.53 460 -37.41 0.0005
2015-08-14 2015-06-30 13F RETROPHIN COM 761299106 22,162 7,721 53.47 735 112.43 0.0009
2015-08-27 2015-03-31 13F/A-1 RETROPHIN COM 761299106 14,441 -27 -0.19 346 95.48 0.0004
2015-05-15 2015-03-31 13F RETROPHIN COM 761299106 14,441 346
2015-02-12 2014-12-31 13F RETROPHIN COM 761299106 14,468 365 2.59 177 39.37 0.0003
2014-11-13 2014-09-30 13F RETROPHIN COM 761299106 14,103 460 3.37 127 -20.62 0.0002
2014-08-19 2014-06-30 13F/A-1 RETROPHIN COM 761299106 13,643 0 160 0.0002
2014-08-28 2014-06-30 13F/A-2 RETROPHIN COM 761299106 13,643 0 160 0.0002
2014-09-15 2014-06-30 13F/A-3 RETROPHIN COM 761299106 13,643 13,643 160 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.